Approval · Notice of Compliance 18186 · 2016
AFINITOR: Notice of Compliance 18186
Issued May 17, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18186
- Date
- May 17, 2016
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: for the treatment of unresectable, locally advanced or metastatic, well differentiated, non-functional neroendocrine tumours (net) of gastroinestinal or lung origin in adults with progressive disease
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AFINITOR | Not yet assigned | — |
Medicinal ingredients
- EVEROLIMUS 2.5 MG per TAB
- EVEROLIMUS 5 MG per TAB
- EVEROLIMUS 10 MG per TAB
- EVEROLIMUS 7.5 MG per TAB